CIK 0001053369
- Non-accelerated filer
- Smaller reporting company
ELITE PHARMACEUTICALS INC /NV/
Sign in to watch- Ticker
- ELTP
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- NJ
- Entity type
- Operating
- EIN
- 223542636
- Phone
- +1 201-750-2646
- Business address
- 165 LUDLOW AVENUE, NORTHVALE, NJ, 07647
- Former names
- ELITE PHARMACEUTICALS INC /DE/
- Open-market buys, last 90 days
- $25,980
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$25,980. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2012-03-20 | NARINE JEENARINE Director | Grant or award | +231,633 | $0.10 | $22K | 63,998,251 |
| 2012-03-20 | DICK CHRIS President & COO | Grant or award | +289,541 | $0.10 | $28K | 740,541 |
| 2012-03-20 | Ward Carter Julian Chief Financial Officer, Sec. | Grant or award | +289,541 | $0.10 | $28K | 715,733 |
| 2012-03-20 | Dash Barry H Director | Grant or award | +231,633 | $0.10 | $22K | 608,519 |
| 2012-03-20 | TREPPEL JERRY Chairman & CEO | Grant or award | +347,448 | $0.10 | $34K | 1,854,341 |
| 2012-03-20 | WHITNELL JEFFREY A Director | Grant or award | +231,633 | $0.10 | $22K | 572,587 |
| 2012-03-16 | NARINE JEENARINE Director | Sale | −85,000 | $0.10 | $9K | 63,766,618 |
| 2012-03-16 | NIGALAYE ASHOK G Chief Scientific Officer | Sale | −85,000 | $0.10 | $9K | 63,766,618 |
| 2012-03-16 | POTTI RAM Director | Sale | −85,000 | $0.10 | $9K | 63,358,669 |
| 2012-03-16 | EPIC PHARMA LLC 10% owner | Sale | −85,000 | $0.10 | $9K | 63,358,669 |
| 2012-03-16 | EPIC INVESTMENTS, LLC 10% owner | Sale | −85,000 | $0.10 | $9K | 63,358,669 |
| 2012-03-15 | EPIC PHARMA LLC 10% owner | Grant or award · Series E Convertible Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | NIGALAYE ASHOK G Chief Scientific Officer | Grant or award · Series E Convertible Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | NARINE JEENARINE Director | Grant or award · Series E Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | EPIC PHARMA LLC 10% owner | Grant or award · Series E Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | POTTI RAM Director | Grant or award · Series E Convertible Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | NARINE JEENARINE Director | Purchase · Series E Convertible Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | NIGALAYE ASHOK G Chief Scientific Officer | Purchase · Series E Convertible Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | POTTI RAM Director | Purchase · Series E Convertible Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
| 2012-03-15 | EPIC PHARMA LLC 10% owner | Purchase · Series E Convertible Preferred Stock | +125 | $1,000.00 | $125K | 1,750 |
Page 24 of 28 · 542 trades